Table 1.
Patient characteristics and specimen numbers from the randomized controlled trial.
| Baseline (n = 167) |
48-Hours (n = 154) |
|||
|---|---|---|---|---|
| Variable | HDIVC (n = 84) |
Placebo (n = 83) |
HDIVC (n = 82) |
Placebo (n = 72) |
| Survived and in the ICU, n (%) | 84 (100) | 83 (100) | 82 (97.6) | 72 (86.7) |
| Age, years (mean, SD) | 52.7 (17.5) | 56.8 (15.7) | 52.3 (17.3) | 55.8 (15.7) |
| Men, n (%) | 45 (53.6) | 45 (54.2) | 44 (53.7) | 39 (54.2) |
| Subjects with ABG available, n (%) | 80 (95.2) | 82 (98.8) | 62 (75.6) | 65 (90.2) |
| Subjects with cfDNA available plasma, n (%) | 84 (100) | 83 (100) | 81 (98.8) | 70 (97.2) |
| Subjects with syndecan-1 available plasma, n (%) | 83 (98.8) | 83 (100) | 80 (96.4) | 70 (97.2) |
Abbreviations: ABG, arterial blood gas; cfDNA, cell-free deoxyribonucleic acid; HDIVC, high-dose intravenous vitamin C. N, number; SD, standard deviation.